Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,142 GBX | -.--% | -2.06% | +8.35% |
May. 08 | UBS raises Centrica to 'buy' from 'neutral | AN |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Property & Casualty Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.35% | 4.98B | C+ | ||
+53.84% | 67.71B | B- | ||
+16.34% | 52.31B | C+ | ||
+19.67% | 44.21B | B- | ||
+38.21% | 38.38B | B- | ||
+77.48% | 33.19B | B | ||
+11.86% | 29.8B | B- | ||
+25.50% | 25.44B | C- | ||
-0.43% | 21.46B | B+ | ||
+15.61% | 21.35B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HSX Stock
- Ratings Hiscox Ltd